EN
中文 EN
Milestones
Home >Who We Are >Milestones
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2012
2011
2009
10余年沉淀 开启新征程
2024
2024
  • 01
    Initiated Phase I clinical trial for VLP-Polio in Australia
  • 02
    Acceptance of drug application for registration for the PCV13i
  • 03
    Initiated Phase Ⅲ clinical trial for Absorbed Tetanus Vaccine
  • 04
    Received positive preliminary results from Phase I clinical trials of the PBPV
  • 05
    Obtained clinical trial approval of the Hib Vaccine
  • 06
    Initiated Phase Ⅲ clinical trial for Menhycia® in Indonesia
  • 10
    VLP-Polio obtained clinical trial approval in Indonesia
  • 10
    Grant agreement reached with the Bill & Melinda Gates Foundation for VLP-Polio and related combined vaccine project
2023
2023
  • 01
    Convidecia Air® approved in Indonesia
  • 02
    Framework Agreement with AstraZeneca on mRNA vaccine
  • 03
    IM & IH of Zoster Vaccine approved for clinical trial in Canada
  • 04
    Convidecia® registered as a pharmaceutical product in Hong Kong, and obtains Halal Decree in Indonesia
  • 05
    Subscription Agreement with Solution Group Berhad
  • 06
    Initiated Phase Ⅰb clinical trial for PBPV
  • 07
    Bivalent COVID-19 mRNA vaccine, Tdcp Adolescent and Adult, and Tetanus vaccine approved for clinical trial
  • 08
    DTcP Infant vaccine entered Phase Ⅲ clinical trial
2022
2022
  • 01
    The Recombinant Novel Coronavirus vaccine Convidecia® approved as heterologous b
  • 02
    The WHO granted the Emergency Use Listing for the Recombinant Novel Coronavirus
  • 03
    Convidecia Air® approved for Emergency Use in Morocco
  • 04
    The world's first inhaled COVID-19 vaccine Convidecia Air® approved as heterolog
2021
2021
  • 01
    The Recombinant Novel Coronavirus Vaccine Convidecia® received approval in over
  • 02
    Menphecia® approved in China
  • 03
    Menhycia® approved in China
2020
2020
  • 01
    Listed on the Sci-Tech Innovation Board of SSE
  • 02
    Completed Convidecia® phase II clinical trial, and launched multi-center phase I
2019
2019
  • 01
    Listed on the main board of HKEX
  • 02
    NDA for MCV2 was accepted by NMPA
  • 03
    NDA for MCV4 was granted with priority review
  • 04
    Obtained CTA approval of PCV13i
2018
2018
  • 01
    Bacterial vaccine manufacturing facility comes into operation
  • 02
    Obtained CTA approval of DTcP
2017
2017
  • 01
    Obtained NDA approval of Ad5-EBOV in China
2016
2016
  • 01
    Completed Ad5-EBOV phase II clinical trial in Sierra Leone
  • 02
    Submitted CTA of PBPV
2015
2015
  • 02
    Obtained CTA approvals of MCV2 & MCV4
  • 02
    Pilot facility passed European QP inspection
2014
2014
  • 01
    Filed CTA for DTcP candidates
  • 02
    Obtained CTA approval of Ad5-EBOV and initiated clinical trial
2012
2012
  • 01
    Completed the construction of GMP standard pilot plant
2011
2011
  • 01
    Incorporated and registered in Tianjin, China
2009
2009
  • 01
    Incorporated and registered in Tianjin, China